XML 59 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Intangible assets - Additional information (Details)
$ in Millions
 1 Months Ended 6 Months Ended
Jun. 01, 2022
USD ($)
Jul. 31, 2023
EUR (€)
Oct. 31, 2022
EUR (€)
Jan. 31, 2022
EUR (€)
Oct. 31, 2020
EUR (€)
Jun. 30, 2020
EUR (€)
Apr. 30, 2020
EUR (€)
Jun. 30, 2019
EUR (€)
Jun. 30, 2024
EUR (€)
Jun. 30, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2023
EUR (€)
Jul. 31, 2017
EUR (€)
Disclosure of detailed information about intangible assets [line items]                          
Intangible assets other than goodwill                 € 119,000 € 903,000 € 1,556,000 € 416,000  
Additional considerations                 0 2,000,000      
Financial liabilities                 35,503,000 € 40,658,000 42,251,000 39,893,000  
2014 Monalizumab (NKG2A) agreement with Novo Nordisk                          
Disclosure of detailed information about intangible assets [line items]                          
Intangible assets other than goodwill                 119,000     € 416,000  
IPH5201 (anti-CD39) rights acquired from Orega Biotech                          
Disclosure of detailed information about intangible assets [line items]                          
Additional considerations   € 2,000,000 € 600,000 € 400,000   € 200,000 € 2,500,000 € 7,000,000          
Agreement related to IPH5201 with AstraZeneca                          
Disclosure of detailed information about intangible assets [line items]                          
Milestone payment received | $ $ 5                        
IPH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S                          
Disclosure of detailed information about intangible assets [line items]                          
Intangible assets other than goodwill                         € 40,000,000
Payments for milestone         € 1,000,000                
Financial liabilities                 € 0        
Impairment of intangible assets                     € 41,000,000